Page last updated: 2024-12-05

pacocf3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4670
CHEMBL ID99344
CHEBI ID186740
SCHEMBL ID4653611
MeSH IDM0283787

Synonyms (35)

Synonym
1,1,1-trifluoroheptadecan-2-one
CHEMBL99344 ,
HMS3267L18
tocris-1460
NCGC00025171-01
HSCI1_000022
pacocf3
bdbm50085494
1,1,1-trifluoro-heptadecan-2-oneor(palmitoyl trifluoromethyl ketone (ptk))
palmityl trifluoromethyl ketone
141022-99-3
CHEBI:186740
1,1,1-triluoroheptadecan-2-one
AKOS017343267
SCHEMBL4653611
1,1,1-trifluoro-2-heptadecanone
1,1,1-trifluoro-2-heptadecanone #
HMS3649G09
DTXSID00274441
sr-01000597566
SR-01000597566-1
palmityl trifluoromethyl ketone, phosholipase a2 inhibitor
J-007449
pacocf - cas 141022-99-3
HMS3676D05
palmityltrifluoromethylketone
SR-01000597566-2
HMS3412D05
2-heptadecanone, 1,1,1-trifluoro-
palmityl trifluoromethylketone
MS-24476
palmityltrifluorometylketone
CS-0029301
HY-108607
mfcd00797669
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alpha-haloketoneA haloketone in which the halogen and oxo substituents are on adjacent carbon atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID504865
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID414232Inhibition of human group 6A iPLA2 by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID414231Inhibition of human group 4A cPLA2 by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID646965Inhibition of human endothelial lipase expressed using recombinant adenovirus using glycerol-tri[9,10(n)-3H]oleate at 50 uM after 1 hr by vesicle assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Design and synthesis of boronic acid inhibitors of endothelial lipase.
AID414230Inhibition of human group 5 sPLA2 at 0.091 mol fraction by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID414228Inhibition of human group 4A cPLA2 at 0.091 mol fraction by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID414229Inhibition of human group 6A iPLA2 at 0.091 mol fraction by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID158962Effect on cytosolic Phospholipase A2 (PLA2) activity at a concentration of 100 uM2000Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3
Synthesis and enzyme inhibitory activities of a series of lipidic diamine and aminoalcohol derivatives on cytosolic and secretory phospholipases A2.
AID646966Inhibition of human lipoprotein lipase expressed using recombinant adenovirus using glycerol-tri[9,10(n)-3H]oleate at 50 uM after 1 hr by vesicle assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Design and synthesis of boronic acid inhibitors of endothelial lipase.
AID158963Effect on cytosolic Phospholipase A2 (PLA2) activity at a concentration of 100 uM2000Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3
Synthesis and enzyme inhibitory activities of a series of lipidic diamine and aminoalcohol derivatives on cytosolic and secretory phospholipases A2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.25 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]